Salarius Pharmaceuticals, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
Decoy Therapeutics Inc. has filed an S-1 registration statement to allow for the resale of up to 3,766,500 shares of common stock by selling stockholders, primarily from warrants issued in a recent private placement.
Salarius Pharmaceuticals completes its merger with Decoy Therapeutics and initiates an $8 million public offering, significantly diluting existing shareholders while pivoting to a new peptide conjugate platform.
Salarius Pharmaceuticals is merging with Decoy Therapeutics, shifting its focus to peptide conjugate drug discovery and raising $6.4M in a public offering.
Salarius Pharmaceuticals and Decoy Therapeutics are progressing with their merger and a new financing round, while Salarius faces imminent Nasdaq delisting for non-compliance with listing rules.
Salarius Pharmaceuticals, facing delisting from Nasdaq and significant financial challenges, is proceeding with a merger with preclinical-stage Decoy Therapeutics and a public offering aiming to raise $6.5 million to fund the combined entity's operations and pipeline.
Salarius Pharmaceuticals is proceeding with a reverse merger with preclinical-stage Decoy Therapeutics, coupled with a public offering, as it faces significant Nasdaq delisting threats and aims to pivot its business focus to novel peptide conjugate therapeutics.
Salarius Pharmaceuticals files an amendment to its S-1 registration statement, updating business and financial information related to its merger with Decoy Therapeutics and responding to SEC comments.
Salarius Pharmaceuticals is set to merge with Decoy Therapeutics, focusing on developing innovative peptide conjugates for infectious diseases and oncology, contingent on a $6 million financing and Nasdaq listing.
Salarius Pharmaceuticals will merge with Decoy Therapeutics in a stock-for-stock transaction, shifting focus to peptide conjugate therapeutics.
Salarius Pharmaceuticals has filed a registration statement for the potential resale of up to 6,733,334 shares of common stock by C/M Capital Master Fund, LP, under an equity line of credit agreement.